Unrelated donor bone marrow transplants in children

Alfred Grovas, Stephen A. Feig, Sheryl O'Rourke, Leonard Valentino, Fran Wiley, Lynne Hunt, Elliot M. Landaw, James Gajewski

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Only a small proportion of children who might benefit from bone marrow transplant (BMT) have an HLA-identical sibling. To provide this potentially curative therapy to patients without a matched related donor, marrow transplants using less well matched related donors or unrelated donors (identified through computerized donor registries) have been performed. We report the outcome of 24 consecutive unrelated donor BMT's performed on children. Eligible diagnosis included acute leukemia (AL) (n = 15), chronic myelogenous leukemia (CML) (n = 4), myelodysplastic syndrome (MDS) (n = 3), and severe aplastic anemia (SAA) (n = 2). All donor/recipient pairs were sero-matched at 5 or 6 of the 6 HLA A, B, and DR antigens. Several different preparative regimens were used, but fractionated total body irradiation (TBI) was used in 20 patients. All recipients received graft-versus-host-disease (GVHD) prophylaxis with cyclosporine-A (CSA), four with short course methotrexate (MTX), 14 in combination with short course MTX and methylprednisolone (MPS), and five in combination with a mouse monoclonal antibody to CD5, coupled to the A-chain of ricin (Xomazyme-65). One patient received CSA and MPS alone after a T-cell depleted marrow transplant. Twenty of 23 evaluable recipients engrafted (87%). Two patients with CML never engrafted and had autologous marrow recovery, one patient with SAA died at 128 days without evidence of engraftment, and there was one early death at day +9. Fourteen of 20 patients (70%) with stable donor-derived hematopoiesis developed significant acute GVHD ≥ grade II). Eleven of 15 engrafted patients who survived > 100 days after BMT developed chronic GVHD (73%). Thirteen patients survive, 10 disease-free; 2 yr actuarial survival and disease-free survival are 47% and 41%, respectively. Of the 19 engrafted patients with leukemia or MDS, only three have relapsed. The actuarial relapse risk at 2 yr is 24%. Unrelated donor transplants in children are associated with an increased risk of GVHD and nonengraftment compared to matched sibling transplants. Increased donor age is significantly associated with a greater risk of acute GVHD.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalCell Transplantation
Volume3
Issue number5
StatePublished - Sep 1994
Externally publishedYes

Fingerprint

Unrelated Donors
Transplants
Bone
Bone Marrow
Grafts
Graft vs Host Disease
Tissue Donors
Aplastic Anemia
Myelodysplastic Syndromes
Methylprednisolone
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Methotrexate
Cyclosporine
Siblings
Leukemia
Monoclonal antibodies
T-cells
Antigens
Ricin
HLA-A Antigens

Keywords

  • Acute graft versus host disease
  • Bone marrow transplantation
  • Children
  • Unrelated donors

ASJC Scopus subject areas

  • Transplantation
  • Cell Biology

Cite this

Grovas, A., Feig, S. A., O'Rourke, S., Valentino, L., Wiley, F., Hunt, L., ... Gajewski, J. (1994). Unrelated donor bone marrow transplants in children. Cell Transplantation, 3(5), 413-420.

Unrelated donor bone marrow transplants in children. / Grovas, Alfred; Feig, Stephen A.; O'Rourke, Sheryl; Valentino, Leonard; Wiley, Fran; Hunt, Lynne; Landaw, Elliot M.; Gajewski, James.

In: Cell Transplantation, Vol. 3, No. 5, 09.1994, p. 413-420.

Research output: Contribution to journalArticle

Grovas, A, Feig, SA, O'Rourke, S, Valentino, L, Wiley, F, Hunt, L, Landaw, EM & Gajewski, J 1994, 'Unrelated donor bone marrow transplants in children', Cell Transplantation, vol. 3, no. 5, pp. 413-420.
Grovas A, Feig SA, O'Rourke S, Valentino L, Wiley F, Hunt L et al. Unrelated donor bone marrow transplants in children. Cell Transplantation. 1994 Sep;3(5):413-420.
Grovas, Alfred ; Feig, Stephen A. ; O'Rourke, Sheryl ; Valentino, Leonard ; Wiley, Fran ; Hunt, Lynne ; Landaw, Elliot M. ; Gajewski, James. / Unrelated donor bone marrow transplants in children. In: Cell Transplantation. 1994 ; Vol. 3, No. 5. pp. 413-420.
@article{096b078d73db47ba89f980adf2fa160e,
title = "Unrelated donor bone marrow transplants in children",
abstract = "Only a small proportion of children who might benefit from bone marrow transplant (BMT) have an HLA-identical sibling. To provide this potentially curative therapy to patients without a matched related donor, marrow transplants using less well matched related donors or unrelated donors (identified through computerized donor registries) have been performed. We report the outcome of 24 consecutive unrelated donor BMT's performed on children. Eligible diagnosis included acute leukemia (AL) (n = 15), chronic myelogenous leukemia (CML) (n = 4), myelodysplastic syndrome (MDS) (n = 3), and severe aplastic anemia (SAA) (n = 2). All donor/recipient pairs were sero-matched at 5 or 6 of the 6 HLA A, B, and DR antigens. Several different preparative regimens were used, but fractionated total body irradiation (TBI) was used in 20 patients. All recipients received graft-versus-host-disease (GVHD) prophylaxis with cyclosporine-A (CSA), four with short course methotrexate (MTX), 14 in combination with short course MTX and methylprednisolone (MPS), and five in combination with a mouse monoclonal antibody to CD5, coupled to the A-chain of ricin (Xomazyme-65). One patient received CSA and MPS alone after a T-cell depleted marrow transplant. Twenty of 23 evaluable recipients engrafted (87{\%}). Two patients with CML never engrafted and had autologous marrow recovery, one patient with SAA died at 128 days without evidence of engraftment, and there was one early death at day +9. Fourteen of 20 patients (70{\%}) with stable donor-derived hematopoiesis developed significant acute GVHD ≥ grade II). Eleven of 15 engrafted patients who survived > 100 days after BMT developed chronic GVHD (73{\%}). Thirteen patients survive, 10 disease-free; 2 yr actuarial survival and disease-free survival are 47{\%} and 41{\%}, respectively. Of the 19 engrafted patients with leukemia or MDS, only three have relapsed. The actuarial relapse risk at 2 yr is 24{\%}. Unrelated donor transplants in children are associated with an increased risk of GVHD and nonengraftment compared to matched sibling transplants. Increased donor age is significantly associated with a greater risk of acute GVHD.",
keywords = "Acute graft versus host disease, Bone marrow transplantation, Children, Unrelated donors",
author = "Alfred Grovas and Feig, {Stephen A.} and Sheryl O'Rourke and Leonard Valentino and Fran Wiley and Lynne Hunt and Landaw, {Elliot M.} and James Gajewski",
year = "1994",
month = "9",
language = "English (US)",
volume = "3",
pages = "413--420",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "5",

}

TY - JOUR

T1 - Unrelated donor bone marrow transplants in children

AU - Grovas, Alfred

AU - Feig, Stephen A.

AU - O'Rourke, Sheryl

AU - Valentino, Leonard

AU - Wiley, Fran

AU - Hunt, Lynne

AU - Landaw, Elliot M.

AU - Gajewski, James

PY - 1994/9

Y1 - 1994/9

N2 - Only a small proportion of children who might benefit from bone marrow transplant (BMT) have an HLA-identical sibling. To provide this potentially curative therapy to patients without a matched related donor, marrow transplants using less well matched related donors or unrelated donors (identified through computerized donor registries) have been performed. We report the outcome of 24 consecutive unrelated donor BMT's performed on children. Eligible diagnosis included acute leukemia (AL) (n = 15), chronic myelogenous leukemia (CML) (n = 4), myelodysplastic syndrome (MDS) (n = 3), and severe aplastic anemia (SAA) (n = 2). All donor/recipient pairs were sero-matched at 5 or 6 of the 6 HLA A, B, and DR antigens. Several different preparative regimens were used, but fractionated total body irradiation (TBI) was used in 20 patients. All recipients received graft-versus-host-disease (GVHD) prophylaxis with cyclosporine-A (CSA), four with short course methotrexate (MTX), 14 in combination with short course MTX and methylprednisolone (MPS), and five in combination with a mouse monoclonal antibody to CD5, coupled to the A-chain of ricin (Xomazyme-65). One patient received CSA and MPS alone after a T-cell depleted marrow transplant. Twenty of 23 evaluable recipients engrafted (87%). Two patients with CML never engrafted and had autologous marrow recovery, one patient with SAA died at 128 days without evidence of engraftment, and there was one early death at day +9. Fourteen of 20 patients (70%) with stable donor-derived hematopoiesis developed significant acute GVHD ≥ grade II). Eleven of 15 engrafted patients who survived > 100 days after BMT developed chronic GVHD (73%). Thirteen patients survive, 10 disease-free; 2 yr actuarial survival and disease-free survival are 47% and 41%, respectively. Of the 19 engrafted patients with leukemia or MDS, only three have relapsed. The actuarial relapse risk at 2 yr is 24%. Unrelated donor transplants in children are associated with an increased risk of GVHD and nonengraftment compared to matched sibling transplants. Increased donor age is significantly associated with a greater risk of acute GVHD.

AB - Only a small proportion of children who might benefit from bone marrow transplant (BMT) have an HLA-identical sibling. To provide this potentially curative therapy to patients without a matched related donor, marrow transplants using less well matched related donors or unrelated donors (identified through computerized donor registries) have been performed. We report the outcome of 24 consecutive unrelated donor BMT's performed on children. Eligible diagnosis included acute leukemia (AL) (n = 15), chronic myelogenous leukemia (CML) (n = 4), myelodysplastic syndrome (MDS) (n = 3), and severe aplastic anemia (SAA) (n = 2). All donor/recipient pairs were sero-matched at 5 or 6 of the 6 HLA A, B, and DR antigens. Several different preparative regimens were used, but fractionated total body irradiation (TBI) was used in 20 patients. All recipients received graft-versus-host-disease (GVHD) prophylaxis with cyclosporine-A (CSA), four with short course methotrexate (MTX), 14 in combination with short course MTX and methylprednisolone (MPS), and five in combination with a mouse monoclonal antibody to CD5, coupled to the A-chain of ricin (Xomazyme-65). One patient received CSA and MPS alone after a T-cell depleted marrow transplant. Twenty of 23 evaluable recipients engrafted (87%). Two patients with CML never engrafted and had autologous marrow recovery, one patient with SAA died at 128 days without evidence of engraftment, and there was one early death at day +9. Fourteen of 20 patients (70%) with stable donor-derived hematopoiesis developed significant acute GVHD ≥ grade II). Eleven of 15 engrafted patients who survived > 100 days after BMT developed chronic GVHD (73%). Thirteen patients survive, 10 disease-free; 2 yr actuarial survival and disease-free survival are 47% and 41%, respectively. Of the 19 engrafted patients with leukemia or MDS, only three have relapsed. The actuarial relapse risk at 2 yr is 24%. Unrelated donor transplants in children are associated with an increased risk of GVHD and nonengraftment compared to matched sibling transplants. Increased donor age is significantly associated with a greater risk of acute GVHD.

KW - Acute graft versus host disease

KW - Bone marrow transplantation

KW - Children

KW - Unrelated donors

UR - http://www.scopus.com/inward/record.url?scp=0028030951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028030951&partnerID=8YFLogxK

M3 - Article

C2 - 7827779

AN - SCOPUS:0028030951

VL - 3

SP - 413

EP - 420

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 5

ER -